Huons Meditech receives Taiwan FDA approval for gynecological drug delivery system 'Jill'SOF'
Huons Meditech receives Taiwan FDA approval for gynecological drug delivery system 'Jill'SOF'
- Electrically powered drug delivery system 'Jill'SOF' & Direct infusion device 'V-needle' begin its first export to Taiwan -
▲ Huons Meditech’s electrically powered drug delivery system 'Jill'SOF'
Huons Meditech, a medical device company of the Huons Group, has begun exporting electrically powered drug delivery system and the dedicated microneedle designed for gynecological use to Taiwan, actively expanding into the global market.
On April 22, Huons Meditech (CEO Lee Jin-suk) announced that it officially received Taiwan Food and Drug Administration (TFDA) approval for 'Jill'SOF' and 'V-needle' and began its first export.
'Jill'SOF' is an electrically powered drug delivery system for treating vaginal dryness. 'Jill'SOF' combines hardware and software specialized for vaginal treatment. The user can easily set the amount and speed of drug delivery, allowing customized treatment for each patient.
'V-needle' is a disposable microneedle used with ‘Jill’SOF’ to ensure the medication is safely and effectively injected into the treatment area, thereby directly improving the condition of vagina.
The procedure using 'Jill'SOF' and 'V-needle' takes about 10 minutes, which is relatively short. In addition, there is almost no pain, so the procedure can be performed without procedural sedation, which allows the patient to return to daily life as soon as possible after the procedure.
CEO of Huons Meditech Lee Jin-suk said, “I am excited to see Huons Meditech’s flagship product 'Jill'SOF' wins its first overseas approval from Taiwan FDA. It is also meaningful for the company that the approval led to the first export. Starting with Taiwan, we will increase ‘Jill’SOF’ brand awareness in the global gynecological device market and accelerate our entry into the global market.”
Huons Meditech is also preparing to launch a cutting-edge drug delivery system, 'Jill'SOF Queen', which integrates benefits of advanced aesthetic technology from 'Dermashine' and intravaginal drug delivery system from 'Jill'SOF'. Huons Meditech aims to obtain TFDA approval within the year.
Huons Meditech offers a new paradigm for ESWT in urology
Huons Meditech drives global growth, participating in medical device symposiums in AU&US
Huons Meditech to showcase at Healthcare Trade Fair ‘Hospitalar 2025’ in Brazil
Huons Meditech receives Taiwan FDA approval for gynecological drug delivery system 'Jill'SOF'
Huons Group participates ‘Dubai Derma 2025’ for efforts to maximize sales
Huons Meditech officially launches Extracorporeal Shock Wave Therapy device ‘IMPO88 Plus’ for Erectile Dysfunction - Proven effect on Chronic Prostatitis/Chronic Pelvic Pain Syndrome Treatment -
Huons Meditech Showcases Innovative Medical Devices at ‘KIMES 2025’
Huons Meditech Showcases at Arab Health 2025 in Dubai
Huons Meditech Launches ‘Premium 9-Pin Needle 31G’ for Skin Booster Treatments
Huons Meditech Showcases Expertise at the ‘Society of Female Functional Urology and Sexual Medicine International Seminar’
Huons Meditech Accelerates Overseas Marketing
Huons Meditech Showcases Key Products at FIME 2024 in Florida